BIOCRYST PHARMACEUTICALS INC (BCRX) competitors & alternatives
Health Care · NASDAQ
BIOCRYST PHARMACEUTICALS INC (BCRX)'s top competitors and alternatives — its most similar public companies — include Ionis Pharmaceuticals (IONS), INTELLIA THERAPEUTICS INC (NTLA), FULCRUM THERAPEUTICS INC (FULC), ATRIUM THERAPEUTICS INC (RNA), KRYSTAL BIOTECH INC (KRYS), Sarepta Therapeutics (SRPT), TONIX PHARMACEUTICALS HOLDING CORP (TNXP), AGIOS PHARMACEUTICALS INC (AGIO), MBX BIOSCIENCES INC (MBX), Perrigo (PRGO), Seaport Therapeutics, Inc. (SPTX) and CULLINAN THERAPEUTICS INC (CGEM). These are BIOCRYST PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top BCRX competitors & alternatives
-
Ionis PharmaceuticalsIONSHealth Care
Pioneer in RNA-targeted antisense medicines with seven commercialized products and expanding late-stage pipeline across rare neurological and cardiometabolic…
$54.01 (as of 2026-07-22) · market cap $8.8B
-
INTELLIA THERAPEUTICS INCNTLAHealth Care
CRISPR-based genome editing company developing in vivo therapies for rare genetic diseases including hereditary angioedema and ATTR amyloidosis.
$11.13 (as of 2026-07-22) · market cap $1.6B
-
FULCRUM THERAPEUTICS INCFULCHealth Care
Fulcrum Therapeutics discovers and develops treatments for genetically-defined rare diseases, with pociredir as a lead clinical-stage program.
$3.70 (as of 2026-07-22) · market cap $248M
-
ATRIUM THERAPEUTICS INCRNAHealth Care
Atrium is an early-stage biotech pioneering antibody-conjugated RNA therapeutics to treat rare genetic cardiomyopathies by silencing disease-driving genes in…
$12.17 (as of 2026-07-22) · market cap $210M
-
KRYSTAL BIOTECH INCKRYSHealth Care
Krystal Biotech is a genetic medicine company leveraging its proprietary HSV-1 vector platform to treat rare diseases, headlined by its FDA-approved topical…
$336.80 (as of 2026-07-22) · market cap $9.9B
-
Sarepta TherapeuticsSRPTHealth Care
A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare…
$15.82 (as of 2026-07-22) · market cap $1.7B
-
TONIX PHARMACEUTICALS HOLDING CORPTNXPHealth Care
A fully-integrated biopharmaceutical company commercializing TONMYA (cyclobenzaprine sublingual tablets) for fibromyalgia while advancing a pipeline of CNS,…
$10.59 (as of 2026-07-22) · market cap $184M
-
AGIOS PHARMACEUTICALS INCAGIOHealth Care
A commercial-stage biopharmaceutical company focused on transforming the treatment landscape for rare genetic hematologic diseases through its innovative…
$36.05 (as of 2026-07-22) · market cap $2.2B
-
MBX BIOSCIENCES INCMBXHealth Care
A clinical-stage biopharmaceutical company leveraging a proprietary platform to optimize drug candidate properties and develop therapies across multiple…
$58.30 (as of 2026-07-22) · market cap $2.9B
-
PerrigoPRGOHealth Care
A struggling diversified consumer and prescription healthcare manufacturer navigating portfolio restructuring and strategic divestitures amid margin pressure…
$10.47 (as of 2026-07-22) · market cap $1.5B
-
Seaport Therapeutics, Inc.SPTXHealth Care
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics using its proprietary drug development platform.
$21.30 (as of 2026-07-22) · market cap $1.1B
-
CULLINAN THERAPEUTICS INCCGEMHealth Care
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases.
$17.65 (as of 2026-07-22) · market cap $1.1B
Not quite? Describe exactly what you want →
Peers are BIOCRYST PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: BIOCRYST PHARMACEUTICALS INC (BCRX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.